Systemic

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Condition:   AsthmaInterventions:   Drug: Fluticasone furoate (FF) Dry Powder Inhaler;   Drug: Fluticasone propionate (FP) Dry Powder Inhaler;   Drug: Budesonide (BUD) Turbuhaler;   Drug: Placebo (ELLIPTA or DISKUS)Sponsor:   GlaxoSmithKlineNot yet recruiting – verified December 2016 View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days




Adult Orbital Xanthogranulomatous Disease: A Review with Emphasis on Etiology, Systemic Associations, Diagnostic Tools, and Treatment.

Adult Orbital Xanthogranulomatous Disease: A Review with Emphasis on Etiology, Systemic Associations, Diagnostic Tools, and Treatment. Dermatol Clin. 2015 Jul;33(3):457-63 Authors: Kerstetter J, Wang J Abstract Adult orbital xanthogranulomatous diseases are rare entities and encompass a group of disorders with…